



Atrion Corporation (ATRI)

Updated December 12th, 2022, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$635	5 Year CAGR Estimate:	6.9%	Market Cap:	\$1.1 B
Fair Value Price:	\$677	5 Year Growth Estimate:	4.0%	Ex-Dividend Date:	3/14/2023
% Fair Value:	94%	5 Year Valuation Multiple Estimate:	1.3%	Dividend Payment Date:	3/31/2023
Dividend Yield:	1.4%	5 Year Price Target:	\$824	Years Of Dividend Growth:	18
Dividend Risk Score:	B	Retirement Suitability Score:	D	Rating:	Hold

Overview & Current Events

Atrion Corporation develops and manufactures products for medical applications. The company's medical products are used in several fields, including cardiovascular, fluid delivery, and ophthalmic applications. The company's fluid delivery products contribute to a significant portion of the company's revenue, accounting for 47% of net revenues for 2021. Cardiovascular products of the company, like Myocardial Protection System, are also popular among customers and formed 34% of the company's sales in 2021. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion Corporation generates the majority of its revenue in the United States.

On November 08, 2022, Atrion Corporation announced its Q3 2022 result, posting total revenues of \$44.6 million, up 3.9% from \$42.9 million in Q3 2021. The diluted earnings per share for the quarter was reported at \$4.94 million, up \$0.36 from \$4.58 in Q3 2022. The operating income stood at \$9.6 million, up \$125 thousand from last year's period.

President and CEO David Battat, while commenting on the quarter's results, noted that despite the negative impact of Hurricane Ian, the company was able to grow its revenues and income in the previous quarter. We see \$19.35 in earnings-per-share for this year following Q3 results.

Growth on a Per-Share Basis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
EPS	\$11.66	\$13.18	\$14.08	\$15.47	\$14.85	\$19.71	\$18.44	\$19.73	\$17.44	\$18.81	\$19.35	\$23.54
DPS	\$2.10	\$2.40	\$2.78	\$3.30	\$3.90	\$4.50	\$5.10	\$5.80	\$6.60	\$7.40	\$8.60	\$15.16
Shares	2.0	2.0	2.0	1.9	1.9	1.9	1.9	1.9	1.8	1.8	1.8	1.7

Atrion Corporation's consistent results, with low volatility in earnings, reflect a consistent demand for the company's products and a solid network with the customer base. Since the company's offerings do not fall in the consumer discretionary category, it makes Atrion Corporation more resilient to changes in business cycles. Defensive healthcare stocks appeal to investors in a challenging macro-environment such as today since these companies tend to have low beta and a solid track record of delivering consistent results. The company has grown its EPS at a CAGR of 5.5% during 2012-2021. From now on, we forecast a modest 4.0% growth in EPS through 2027, in line with the company's growth prospects and long-term EPS growth rate. In addition, the company will be able to grow its dividends at a healthy pace in the future and has assumed a dividend growth rate of 12.0% for the next five years.

Valuation Analysis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Avg. P/E	18.1	17.8	21.9	23.9	28.9	29.8	35.4	40.8	36.4	35.3	32.8	35.0
Avg. Yld.	1.0%	1.0%	0.9%	0.9%	0.9%	0.8%	0.8%	0.7%	1.0%	1.1%	1.4%	1.8%

Atrion Corporation is trading at a forward P/E of 32.8, slightly lower than the five-year average P/E of 35.5. There is a potential for multiple re-rating given the company continues to post solid results amidst a challenging environment. Given the current environment of interest rates, consistent long-term growth, and prospective M&A activity since ATRI could be an attractive target, we have assumed a P/E of 35.0 to value the company in 2027, in line with the company's 5-year average P/E.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Atrion Corporation (ATRI)

Updated December 12th, 2022, by Yiannis Zourmpanos

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Payout	18%	18%	20%	21%	26%	23%	28%	29%	38%	39%	44%	64%

Atrion Corporation's solid cash generation ability is reflected in its solid payout ratio over the years. The company's five-year average payout ratio stands at 31.4%, and the company has been able to grow dividends at a CAGR of 13.8% during 2017-2022. Moreover, Atrion Corporation has increased its dividend payment to shareholders for the previous 18 years. In addition, Atrion Corporation is at low risk of getting impacted by a possible recession since the company's products don't fall in the discretionary category. However, it is to be noted that the company is a relatively small player in the industry, and some of its competitors have greater financial resources and the ability to invest heavily in R&D to help them capture more market share in the future.

Final Thoughts & Recommendation

We could have been more confident about ATRI, but ROCE has decreased by around 20% during the past five years. However, given that both revenue and the number of assets used in the business have increased, it may indicate that the company is investing in expansion and that the additional capital has temporarily reduced ROCE. If these investments turn out to be profitable, this is encouraging for the long-term performance of stocks. Therefore, as a defensive healthcare company, we believe that the company is well-positioned to continue to do well in the near term. However, our Hold rating is premised upon the 6.9% annualized total returns for the medium-term, with the forecasted earnings-per-share growth of 4.0% and 1.4% dividend yield.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)



Atrion Corporation (ATRI)

Updated December 12th, 2022, by Yiannis Zourmpanos

Income Statement Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Revenue	119	132	141	146	143	147	152	155	148	165
Gross Profit	56	63	69	71	68	71	72	71	66	69
Gross Margin	47.2%	47.8%	48.7%	48.7%	47.1%	48.3%	47.1%	45.6%	44.8%	42.0%
SG&A Exp.	19	21	22	22	22	24	25	25	25	28
D&A Exp.	8	9	9	9	9	9	9	11	12	13
Operating Profit	34	38	41	43	39	41	42	41	36	36
Op. Margin	28.2%	28.7%	29.0%	29.2%	27.3%	28.2%	27.4%	26.1%	24.2%	21.8%
Net Profit	24	27	28	29	28	37	34	37	32	33
Net Margin	19.8%	20.1%	19.8%	19.8%	19.2%	25.0%	22.5%	23.7%	21.8%	20.0%
Free Cash Flow	19	27	19	31	27	37	26	22	17	23
Income Tax	11	13	14	12	12	6	8	6	6	5

Balance Sheet Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Assets	156	172	172	164	182	204	231	262	267	267
Cash & Equivalents	8	29	21	28	20	30	59	45	22	32
Acc. Receivable	13	14	17	17	17	17	17	19	16	21
Inventories	24	26	28	30	29	29	34	42	50	51
Goodwill & Int.	11	13	12	12	12	12	11	11	11	11
Total Liabilities	21	23	22	20	19	19	20	24	26	23
Accounts Payable	4	4	5	4	4	4	5	6	7	7
Long-Term Debt	-	-	-	-	-	-	-	-	-	-
Total Equity	135	149	150	144	163	184	211	238	240	244
LTD/E Ratio	-	-	-	-	-	-	-	-	-	-

Profitability & Per Share Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Return on Assets	14.9%	16.2%	16.2%	17.2%	15.9%	19.0%	15.7%	14.9%	12.1%	12.4%
Return on Equity	17.3%	18.7%	18.6%	19.7%	18.0%	21.1%	17.3%	16.4%	13.4%	13.6%
ROIC	17.3%	18.7%	18.6%	19.7%	18.0%	21.1%	17.3%	16.4%	13.4%	13.6%
Shares Out.	2.0	2.0	2.0	1.9	1.9	1.9	1.9	1.9	1.8	1.8
Revenue/Share	58.74	65.44	71.27	77.93	77.27	78.94	82.05	83.23	80.17	90.76
FCF/Share	9.38	13.35	9.39	16.63	14.41	20.12	13.85	11.82	9.42	12.63

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.